证券代码： 688602 证券简称： 康鹏科技 公告编号： 2025-044 上海康鹏科技股份有限公司 本次上市流通的限售股属于公司首次公开发行战略配售限售股。自本次上市 的限售股形成至今，公司未发生因利润分配、公积金转增等导致股本数量变化的 情况。 三、 本次上市流通的限售股的有关承诺 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式 为网下，上市股数为4,618,937股。本公司确认，上市流通数量等于该限售期的全 部战略配售股份数量。 本次股票上市流通总数为4,618,937股。 ? 本次股票上市流通日期为2025 年 7 月 21 日（因 2025 年 7 月 20 日为非交 易日，故上市流通日期顺延至下一交易日）。 一、 本次上市流通的限售股类型 有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1007 号）同意注册， 上海康鹏科技股份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）10,387.50 万 ...

证券代码：688602 证券简称：康鹏科技 公告编号：2025-044 上海康鹏科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发战略配售股份（限售期 24 月）；股票认购方式 为网下，上市股数为4,618,937股。本公司确认，上市流通数量等于该限售期的全 部战略配售股份数量。 本次股票上市流通总数为4,618,937股。 本次股票上市流通日期为2025 年 7 月 21 日（因 2025 年 7 月 20 日为非交 易日，故上市流通日期顺延至下一交易日）。 截至本公告披露日，本次申请上市流通的限售股股东严格履行相应的承诺事 项，不存在相关承诺未履行影响本次限售股上市流通的情况。 一、 本次上市流通的限售股类型 2023 年 5 月 9 日，经中国证券监督管理委员会《关于同意上海康鹏科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1007 号）同意注册， 上海康鹏科技股份有限公司（以下简称"公司"）首次公开发行人 ...

中信建投证券股份有限公司（以下简称"中信建投证券"、"保荐机构"） 作为上海康鹏科技股份有限公司（以下简称"公司"、"康鹏科技"）首次公开 发行股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》等相关规定，对康鹏科技 首次公开发行部分限售股上市流通的事项进行了核查，具体情况如下： 一、 本次上市流通的限售股类型 2023 年 5 月 9 日，经中国证券监督管理委员会《关于同意上海康鹏科技股 份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕1007 号）同意注 册，上海康鹏科技股份有限公司（以下简称"公司"）首次公开发行人民币普通 股（A 股）10,387.50 万股，并于 2023 年 7 月 20 日在上海证券交易所科创板挂 牌上市。公司首次公开发行后，总股本为 51,937.50 万股，其中有限售条件流通 股为 43,464.6325 万股，无限售条件流通股为 8,472.8675 万股。 本次上市流通的限售股为公司首次公开发行战略配售限售股，限售期为自公 司首次公开发行股票上市之日起 24 个月。本次涉及限售股东数量为 1 名 ...

Core Viewpoint - Kangpeng Technology is strategically expanding its presence in the pharmaceutical sector, particularly focusing on peptide business as a key development direction [1][2]. Group 1: Strategic Focus - In March 2025, Kangpeng Technology approved a project to enhance the manufacturing capacity of medical peptides, planning to invest 75 million yuan, marking a significant shift from traditional fine chemicals to innovative pharmaceutical raw materials [2]. - The company has a history of collaboration with pharmaceutical innovators, leveraging its technical advantages in the early stages of raw material drug development [2]. - Kangpeng Technology has accumulated 115 patents, including 66 invention patents, with core technologies centered around fluorination and carbon-carbon coupling, providing a solid foundation for peptide business development [2]. Group 2: R&D Breakthrough - In 2024, despite facing short-term pressure from intensified competition and weak market demand, Kangpeng Technology's R&D investment reached 85.39 million yuan, accounting for 12.65% of revenue, reflecting a commitment to a technology-driven strategy [3]. - The company is optimizing its new materials segment through dual strategies of process optimization and market expansion, with a complete industrial chain expected from the liquid crystal project in Quzhou [3]. - Kangpeng Technology has established stable partnerships with major pharmaceutical companies, including Merck, Eli Lilly, and Bayer, which positions it well for growth in the peptide raw material business [3]. Group 3: Compliance Operations - Kangpeng Technology emphasizes compliance and risk management, as evidenced by a recent legal dispute resolution that reduced the principal amount owed by 1.34 million yuan [5]. - The company has demonstrated transparency in information disclosure and has implemented a restricted stock incentive plan for 160 core personnel, signaling a commitment to long-term growth [6]. Group 4: Future Outlook - The company's focus on peptide business aligns with the growing demand for innovative drug raw materials, supported by government policies aimed at enhancing the drug pricing mechanism and promoting innovative drugs [7]. - With the advancement of the medical peptide manufacturing capacity enhancement project and the conversion of R&D investments into technological barriers, Kangpeng Technology is expected to achieve breakthroughs in the peptide sector, enriching its product pipeline in the pharmaceutical field [7].

Summary of Key Points Core Viewpoint - The announcement details the shareholding changes and the results of the share reduction plan by major shareholders of Shanghai Kangpeng Technology Co., Ltd, indicating a significant reduction in their holdings and the implications for the company's governance structure. Group 1: Shareholding Information - Before the reduction plan, major shareholders Wuxi Yunhui and its concerted party held a total of 45,000,860 shares, accounting for 8.66% of the total share capital of the company [2] - Another group of shareholders, including Tongxiang Yunhui and its concerted parties, held a total of 28,300,094 shares, representing 5.45% of the total share capital [2] Group 2: Reduction Plan Implementation Results - On March 10, 2025, the company disclosed a share reduction plan, allowing Wuxi Yunhui and Xingyu Huitian to reduce their holdings by up to 15,581,250 shares, which is 3% of the total shares [3][4] - The reduction was planned to occur through centralized bidding and block trading from April 1 to June 30, 2025 [3][4] - By the end of the reduction period, Wuxi Yunhui and Xingyu Huitian had reduced their holdings by 14,130,441 shares, while Tongxiang Yunhui and its concerted parties reduced their holdings by 13,281,823 shares [4] Group 3: Changes in Shareholding Rights - Wuxi Yunhui and its concerted party reduced their holdings by 3,630,441 shares, decreasing their total shares from 34,500,860 to 30,870,419, which reduced their ownership percentage from 6.64% to 5.94% [5][9] - The reduction triggered a change that touched the 1% threshold, indicating a significant shift in shareholder structure [9] Group 4: Legal Proceedings and Financial Impact - The company’s wholly-owned subsidiary, Lanzhou Kangpeng, is involved in a legal dispute regarding a construction contract, with a judgment requiring payment of 52,953,288.97 yuan plus interest [14][17] - The estimated impact on the company's 2025 financial results is projected to be 73,000 yuan, with the company indicating that the ongoing legal matters are not expected to significantly affect its operations [14][17]

Group 1 - *ST San Sheng (002742.SZ): The controlling shareholder Pan Xianwen's judicial auction of 32.2 million shares has been completed, with 30 million shares transferred, accounting for 6.94% of the total share capital. After the reduction, Pan Xianwen's shareholding ratio decreased from 24.20% to 17.26%, which will not lead to a change in company control [1] - Aike Co., Ltd. (300889.SZ): Shareholder Zhang Fengbin, holding over 5%, reduced his stake by 1% (1.67818 million shares) from May 13 to June 27, 2025, bringing his holding to 7.9902% [1] - Anlu Technology (688107.SH): The shareholder National Integrated Circuit Industry Investment Fund Co., Ltd. completed its reduction plan, selling 4.008493 million shares (1% of total share capital) from May 8 to June 30, 2025, with a total reduction amount of 109.36 million yuan, current holding ratio at 5.76% [1] Group 2 - Anshuo Information (300380.SZ): The controlling shareholder Shanghai Anshuo Technology Development Co., Ltd. and actual controllers reduced their stakes by 1.16% (1.599416 million shares), 0.94% (1.300187 million shares), and 0.65% (900,000 shares) respectively [1] - Baoming Technology (002992.SZ): Directors and management plan to reduce their holdings by a total of 0.0107%, 0.0714%, and 0.0107% over the next three months [2] - Beiyikang (870199.BJ): Employee shareholding platforms completed their reduction plans, selling 546,284 shares (0.8%) and 131,650 shares (0.19%) [2] Group 3 - Boyun New Materials (002297.SZ): Major shareholder Hunan Xiangtou High-tech Venture Capital Co., Ltd. reduced its stake by 406.74 million shares (0.71%) from June 5 to June 30, 2025, bringing its holding to 6.99% [2] - Dongwei Technology (688700.SH): Specific shareholder Xie Yulong completed a reduction plan, selling 574,857 shares (0.1927%) from June 4 to June 30, 2025, with a total reduction amount of 21.362156 million yuan, current holding ratio at 0% [2] - Fuzhi Environmental Protection (688335.SH): Major shareholder Deqing Junjie Enterprise Management Partnership plans to reduce up to 4.441035 million shares (3%) over the next three months [3] Group 4 - Gu Gao Technology (301510.SZ): Shareholder Beijing Equity Investment Development Management Center completed its reduction plan, selling 4.0001 million shares (1%) from June 5 to June 30, 2025, bringing its holding to 7.68% [3] - Guangbo Co., Ltd. (002103.SZ): Shareholder Ren Hangzhong reduced his stake by 156,440 shares (0.2928%), bringing his holding to 9.99999% [3] - Guoke Military Industry (688543.SH): Specific shareholders Yang Minghua and Chen Gonglin plan to reduce up to 2.08842 million shares (1%) and 3.789115 million shares (1.8143%) over the next three months [3] Group 5 - Guorui Technology (300600.SZ): Major shareholder Gong Ruiliang reduced his stake by 3.243209 million shares (1.1%) from June 27 to July 1, 2025, bringing his holding to 20.63% [4] - Hangzhou Thermal Power (605011.SH): Shareholder Huashi Investment plans to reduce up to 5.997 million shares (1.4989%) over the next three months [4] - Huaya Intelligent (003043.SZ): Executives plan to reduce their holdings by a total of 0.0132%, 0.0092%, and 0.0092% over the next three months [4]

Group 1 - The company’s wholly-owned subsidiary, Lanzhou Kangpeng, is involved in a construction contract dispute with Shanghai Tianyi Decoration Engineering Co., Ltd., which has led to a lawsuit filed in the Gansu Provincial Intermediate People's Court [1] - Lanzhou Kangpeng raised an objection to the jurisdiction during the submission of the defense, and the Gansu Provincial High People's Court ruled on August 29, 2023, to revoke the previous civil ruling and designate the case to be under the jurisdiction of the Lanzhou New District People's Court [1][2] - The recent final judgment from the Gansu Provincial Intermediate People's Court ordered Lanzhou Kangpeng to pay an engineering fee of 52,953,288.97 yuan, along with interest calculated based on the one-year Loan Prime Rate (LPR) from March 30, 2023, until the payment is completed [2][3] Group 2 - The company has accounted for the estimated engineering fee and interest totaling 3.28 million yuan in its 2024 profit and loss statement, with an expected impact of 730,000 yuan on the 2025 profit and loss statement [3] - The company anticipates that this lawsuit will not have a significant adverse effect on its production and operations, as all business operations are currently normal [3]

证券代码：688602 证券简称：康鹏科技 公告编号：2025-042 上海康鹏科技股份有限公司 持股 5%以上股东权益变动触及 1%刻度 暨减持股份结果公告 大宗交易方式减持不超过 10,387,500 股，占公司总股本的比例不超过 2%，自减 持计划发布之日起 15 个交易日后的 3 个月内（2025 年 4 月 1 日至 2025 年 6 月 30 日）实施。 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，上海康鹏科技股份有限公司（以下简称"公司"或"康 鹏科技"）股东无锡云晖新汽车产业投资管理合伙企业（有限合伙）（以下简称"无 锡云晖"）及其一致行动人宁波梅山保税港区星域惠天投资管理合伙企业（有限 合伙）（以下简称"星域惠天"）合计持有公司股份 45,000,860 股，占公司总股 本的 8.66%。 股东桐乡云汇股权投资基金合伙企业（有限合伙）（以下简称"桐乡云汇"） 及其一致行动人桐乡稼沃云枫股权投资合伙企业（有限合伙）（以下简称"桐乡 稼沃 ...

证券代码：688602 证券简称：康鹏科技 公告编号：2025-043 上海康鹏科技股份有限公司 关于子公司诉讼结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 由兰州新区人民法院管辖。 2024 年 12 月 30 日，兰州康鹏收到甘肃省兰州市兰州新区人民法院作出的 （2023）甘 0191 民初 4056 号民事判决书，具体内容详见公司于 2025 年 1 月 4 日在上海证券交易所网站（www.sse.com.cn）披露的《关于子公司诉讼进展的公 告》(公告编号:2025-008)。2025 年 1 月 13 日，兰州康鹏不服该判决结果，提 出上诉，案件由甘肃省兰州市中级人民法院受理。 重要内容提示： 一、诉讼的基本情况 公司全资子公司兰州康鹏与上海天艺建筑装饰工程有限公司（以下简称"天 艺公司"）因建设工程施工合同纠纷，被天艺公司起诉至甘肃省兰州市中级人民 法院。 在提交答辩状期间，兰州康鹏对管辖权提出异议，兰州市中级人民法院于 2023 年 4 月 24 日做出(2023)甘 01 民初 311 号民事 ...

Core Viewpoint - The company has announced the grant of reserved restricted stocks under its 2024 incentive plan, with a total of 712,000 shares to be awarded at a price of 5.32 yuan per share on June 17, 2025, to 55 eligible recipients [1][11]. Summary by Sections 1. Restricted Stock Grant Details - The reserved restricted stock grant date is set for June 17, 2025 [1]. - A total of 712,000 shares will be granted at a price of 5.32 yuan per share [1]. - The incentive plan involves the second category of restricted stocks [1]. 2. Decision-Making Process and Disclosure - The company has followed the necessary decision-making procedures and disclosed relevant information regarding the incentive plan [2]. - The supervisory board has verified the details of the incentive plan and issued a verification opinion [2]. 3. Compliance with Grant Conditions - The board has confirmed that all conditions for granting the restricted stocks have been met, including compliance with relevant laws and regulations [4][5]. - The company has not encountered any disqualifying circumstances for the grant of stocks [5]. 4. Vesting Arrangements - The vesting schedule includes a first vesting period of 50% after 12 months and a second vesting period after 24 months [5]. - The restricted stocks cannot be transferred or pledged before vesting [5]. 5. Impact on Financial Status - The total estimated expense for the stock grant is 2.4947 million yuan, which will be amortized over the vesting period [9]. - The incentive plan is expected to have a minor impact on net profit, but it is anticipated to enhance company performance significantly [9]. 6. Legal Opinions - The legal opinion confirms that all necessary approvals and authorizations for the stock grant have been obtained, and the grant conditions are valid [11].